Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2014
A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Adjusted Indirect and Mixed Comparisons of Drug Therapy for Neuropathic Cancer Pain.Pain research & management · 2026Pooled it
- BeyondFrontiers in pain research (Lausanne, Switzerland) · 2025Pooled it
- Evidence-Based Treatment of Pain in Chemotherapy-Induced Peripheral Neuropathy.Current pain and headache reports · 2023Pooled it
- Treatment for chemotherapy-induced peripheral neuropathy: A systematic review of randomized control trials.Frontiers in pharmacology · 2022Pooled it
- The effect of analgesics on stimulus evoked pain-like behaviour in animal models for chemotherapy induced peripheral neuropathy- a meta-analysis.Scientific reports · 2019Pooled it
- Association of Pain With Mental and Physical Function in Patients With Chemotherapy-Induced Peripheral Neuropathy: A Secondary Analysis From Two Randomized Controlled Trials.Muscle & nerve · 2026Trial
- High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience.Medical oncology (Northwood, London, England) · 2017Trial
- Topical Pain Management: An Updated Review of Current Evidence and Emerging Strategies.Journal of clinical medicine · 2026Review
- Harnessing spatiotemporal melatonin delivery from engineered platforms for targeted microenvironment remodeling in peripheral neuropathy.Materials today. Bio · 2026Review
- Treatment of neuropathic pain in cancer survivors: a scoping review of pharmacological, exercise, and psychosocial interventions.Acta oncologica (Stockholm, Sweden) · 2026Article
- Topical analgesics for neuropathic pain: an evidence-informed guide for the practicing clinician.Pain medicine (Malden, Mass.) · 2026Review
- Chemotherapy-induced peripheral neuropathy in breast cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Chronic Pain in the Cancer Survivor.Current pain and headache reports · 2025Review
- Chemotherapy-induced peripheral neuropathy in patients with breast cancer treated with taxanes (Review).Oncology letters · 2025Review
- Emerging targets and translational challenges in treating paclitaxel-induced peripheral neuropathy.Molecular biology reports · 2025Review
- Multiday intravenous ketamine infusion therapy for the management of central sensitisation syndrome secondary to chronic chemotherapy-induced peripheral neuropathic pain.BMJ case reports · 2025Article
- Examination of the relationship between serum zinc levels and peripheral neuropathy induced by paclitaxel/carboplatin combination therapy in gynecological cancer patients.Fujita medical journal · 2025Article
- The role of ketamine and its enantiomer in managing depression and pain in cancer patients: A narrative review.Journal of anesthesia and translational medicine · 2024Article
- Chemotherapy-Induced Peripheral Neuropathy: A Recent Update on Pathophysiology and Treatment.Life (Basel, Switzerland) · 2024Review
- The Efficacy of Ketamine for Acute and Chronic Pain in Patients with Cancer: A Systematic Review of Randomized Controlled Trials.Healthcare (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeChemotherapy-induced peripheral neuropathy (CIPN) occurs in as high as 70% of patients receiving certain types of chemotherapy agents. The FDA has yet to approve a therapy for CIPN. The aim of this multicenter, phase III, randomized, double-blind, placebo-controlled trial was to investigate the efficacy of 2% ketamine plus 4% amitriptyline (KA) cream for reducing CIPN.
methodsCancer survivors who completed chemotherapy at least 1 month prior and had CIPN (>4 out of 10) were enrolled (N=462). CIPN was assessed using average scores from a 7-day daily diary that asks patients to rate the average "pain, numbness, or tingling in [their] hands and feet over the past 24 h" on an 11-point numeric rating scale at baseline and 6 weeks post intervention. ANCOVA was used to measure differences in 6-week CIPN with effects including baseline CIPN, KA treatment arm, and previous taxane therapy (Y/N).
resultsThe KA treatment showed no effect on 6-week CIPN scores (adjusted mean difference=-0.17, p=0.363).
conclusionsThis study suggests that KA cream does not decrease CIPN symptoms in cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.